TY - JOUR
T1 - Intensive glucose control after allogeneic hematopoietic stem cell transplantation
T2 - A retrospective matched-cohort study
AU - Fuji, S.
AU - Kim, S. W.
AU - Mori, S.
AU - Kamiya, S.
AU - Yoshimura, K.
AU - Yokoyama, H.
AU - Kurosawa, S.
AU - Saito, B.
AU - Takahashi, T.
AU - Kuwahara, S.
AU - Heike, Y.
AU - Tanosaki, R.
AU - Takaue, Y.
AU - Fukuda, T.
N1 - Funding Information:
We thank the medical, nursing, data processing, laboratory and clinical staffs at the National Cancer Center Hospital for their important contributions to this study through dedicated care of the patients. We are indebted to Y Iisaka for assisting with data collection. We also thank S Saito for helping to prepare the article. This study was supported in part by grants from the Ministry of Health, Labor and Welfare, Japan.
PY - 2009
Y1 - 2009
N2 - Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, P <0.001) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46%, P = 0.004, 9 vs 39%, P = 0.002, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37%, P = 0.36) and the elevation of C-reactive protein (18 vs 38%, P = 0.13). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.
AB - Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, P <0.001) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46%, P = 0.004, 9 vs 39%, P = 0.002, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37%, P = 0.36) and the elevation of C-reactive protein (18 vs 38%, P = 0.13). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.
UR - http://www.scopus.com/inward/record.url?scp=68149129628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68149129628&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.431
DO - 10.1038/bmt.2008.431
M3 - Article
C2 - 19151794
AN - SCOPUS:68149129628
SN - 0268-3369
VL - 44
SP - 105
EP - 111
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 2
ER -